Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant

Onkologie

Volumn 32, Issue 1-2, 2009, Pages 30-34

  Abbrederis, Kathrin ^a   Lorenzen, Sylvie ^a   Rothling, Nadine ^b   Ihbe Heffinger, Angela ^c   Schuster, Tibor ^b   Peschel, Christian ^a   Lordick, Florian ^d  

^a 3 Medizinische Klinik Hämatologie Onkologie

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aprepitant; Chemotherapy induced nausea and vomiting; Gastrointestinal tumors; Neurokinin 1 receptor

Indexed keywords

APREPITANT; CAPECITABINE; CETUXIMAB; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANISETRON; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MEGADOSE; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PANCREAS CANCER; SECONDARY PREVENTION; TREATMENT RESPONSE;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; MIDDLE AGED; NAUSEA; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME; VOMITING;

EID: 60249090036     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000183735     Document Type: Article

References (20)

1. Roila F, Bracardia S, Tonato M, Maranglo M, Bella M, Donati D: Ondansetron in the prophylaxis of acute and delayed cisplatin-induced emesis. Clin Oncol 1990;2:268-272.
2. Hesketh P: Management of cisplatin-induced delayed emesis. Oncology 1996;1:78-85.
3. Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-2494.
4. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-1449.
5. Massa E, Astara G, Madeddu C, Dessì M, Loi C, Lepori S, Mantovani G: Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response. Crit Rev Oncol Hematol. 2008, in press.
6. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S: Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108-114.
7. Gralla RJ, Rittenberg C, Peralta M, Lettow L, Cronin M: Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. Oncology 1996;1:86-91.
8. Grunberg SM, Deuson RR, Mavros P: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-2268.
9. The Italian Group for Antiemetic Research: Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000;342:1554-1559.
10. Perez EA, Hesketh P, Sandbach J: Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16:754-760.
11. Kaizer L, Warr D, Hoskins P: Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:1050-1057.
12. The Italian Group for Antiemetic Research: Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients? Ann Oncol 1997;8:561-567.
13. 1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-410.
14. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skorbienda F: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-2830.
15. Lordick F, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier J, Davies G, Deuson R: Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 2007;43:299-307.
16. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-1442.
17. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971-2994.
18. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L: Determinants of post chemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 1997;15:116-123.
19. Pollera CF, Giannarelli D: Prognostic factors influencing cisplatin-induced emesis. Cancer 1989;64:1117-1122.
20. Oechsle K, Müller MR, Hartmann JT, Kanz L, Bokemeyer C: Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie 2006;29:557-561.